ResMed

Current directors and officers who also hold a role at another S&P 500 company.

• Carol BurtIQV · Director
• Christopher DeloreficeULTA · CFO
• Michael J. FarrellZBH · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Aug 17, 2026

   On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026. Mr. Taylor’s intention to retire is not due to any disagreement with Resmed on any matter relating to Resmed’s operations, policies or practices. In connection with Mr. Taylor’s retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

   Read the 8-K filing
2. Apr 30, 2026

   On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. Mr. Sandercock will continue to serve as Chief Financial Officer until May 4, 2026, immediately following which he will become Special Advisor to Mick Farrell, Chairman and Chief Executive Officer through December 31, 2026. Mr. Sandercock will continue to receive his current salary, benefits and vesting of long-term equity incentives and will remain eligible for a six month, pro-rata payment of his short-term incentive for fiscal year 2027. From January 1, 2027, through December 31, 2027, Mr. Sandercock will continue as Special Advisor to Mr. Farrell in a consulting role.

   Read the 8-K filing
3. Nov 20, 2025

   Richard Sulpizio did not seek re-election at the Annual Meeting (as defined below); his term expired on November 19, 2025 at the conclusion of the Annual Meeting, creating a vacancy on our board of directors. On November 19, 2025, our board of directors approved reducing the number of directors serving on our board from twelve (12) to eleven (11). ResMed Inc. 2009 Incentive Award Plan On November 19, 2025, at the 2025 annual meeting of stockholders of ResMed Inc. (the “Annual Meeting”), our stockholders approved an amendment and restatement (the “2009 Plan Amendment”) of the ResMed Inc. 2009 Incentive Award Plan, as Amended and Restated (the “2009 Plan”) and as noted in

   Read the 8-K filing
4. Aug 18, 2025

   Election of Nicole Mowad-Nassar to Board of Directors On August 15, 2025, Resmed Inc. (“Resmed”) elected Nicole Mowad-Nassar to serve on its board of directors effective immediately with an initial term expiring at Resmed’s 2025 annual meeting of stockholders on November 19, 2025, or until Ms. Mowad-Nassar’s earlier death, disability, resignation or removal. Ms. Mowad-Nassar, age 54, is the senior vice president, AbbVie Inc. (NYSE: ABBV) and president, specialty and U.S. therapeutics operations, and has served in these roles since July 2023. Previously, she served as vice president, commercial analytics and operations, AbbVie Patient Services from January 2020 to July 2023 and vice president, commercial analytics and operations and global commercial integration lead, Allergan Acquisition from January 2018 to January 2020. Ms.

   Read the 8-K filing
5. Aug 1, 2025

   (b) On July 28, 2025, Bobby Ghoshal our chief commercial officer, residential care software business (“RCS”) notified us that he intends to resign effective August 1, 2025, to pursue an opportunity as chief operating officer of a software company in a non-competitive industry from ours.

   Read the 8-K filing
6. Aug 16, 2024

   On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024, or until Mr. DelOrefice’s earlier death, disability, resignation or removal. Mr. DelOrefice, age 53, is the executive vice president and chief financial officer of Becton Dickinson and Company and has served in that role since September 2021. Previously, he served as Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021 and Chief Financial Officer of North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018. Mr. DelOrefice will serve on ResMed’s audit committee. Mr. DelOrefice was not selected to serve on ResMed’s board of directors under any arrangement or understanding between Mr. DelOrefice and any other person.

   Read the 8-K filing
7. Nov 9, 2023

   On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024. Mr. Douglas has served as an executive officer of ResMed for over twelve years. Until his retirement, Mr. Douglas will continue to receive his current salary, benefits, and vesting of long-term equity incentives. In connection with his retirement, we have agreed that Mr. Douglas will remain eligible for a pro-rata portion of his short-term incentive cash payment for fiscal year 2024, on the same basis as similarly situated executives, based on his continued employment through December 31, 2023, even though he will not be employed on the date of the payment. From January 2, 2024, through December 31, 2024, Mr.

   Read the 8-K filing
8. Mar 30, 2023

   On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023. Mr. Pendarvis has served as an executive officer of ResMed for over 20 years and intends to retire after a 39-year career in law and business. In accordance with ResMed’s ongoing executive officer succession planning process, we have initiated an internal candidate search to identify Mr. Pendarvis’ successor and ensure a smooth transition. Until the effective date of his retirement, Mr. Pendarvis will continue to receive his current salary, benefits, and vesting of long-term equity incentives. In connection with the retirement, we have agreed that Mr.

   Read the 8-K filing
9. Jan 26, 2023

   On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors. Mick Farrell is our chief executive officer and a current director. The appointment was effective immediately. Dr. Peter C. Farrell, our founder, who has served as chair of the board of directors since the company was founded in 1989, will continue as a director and as a non-officer employee of ResMed. In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately. Ron Taylor will continue to serve as our lead director. There are no compensation changes in connection with any of these appointments. On January 26, 2023, we issued the press release furnished as Exhibit 99.2. The press release announces the board position changes described above.

   Read the 8-K filing
10. Jul 1, 2022

    On June 28, 2022, we announced that we are promoting Lucile Blaise, age 51, to serve as our president, sleep and respiratory care business. The promotion is effective July 1, 2022. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K. Ms. Blaise, previously ResMed’s vice president of sleep & respiratory care for Western Europe, is a medtech industry thought leader with over 25 years’ experience in medical device sales, marketing, finance, and business development. Since June 2015, Ms. Blaise has served as ResMed’s vice president of sleep & respiratory care for Western Europe. From September 2012 to June 2015, she served as ResMed’s vice president, France and North Africa. From November 2019 to September 2012, she served as marketing director - France, and from November 2006 to November 2009, she served as ventilation product manager for ResMed.

    Read the 8-K filing
11. May 11, 2022

    On May 5, 2022, we announced that Jim Hollingshead resigned as our president – sleep and respiratory care business, effective as of May 5, 2022, to pursue an opportunity with a new employer. In connection with his resignation, Robert (“Rob”) Douglas, our president and chief operating officer, has been appointed to serve as our interim president – sleep and respiratory care business. We intend to commence a search for a permanent president – sleep and respiratory care business. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K. Mr. Douglas was appointed ResMed Inc.’s president in March 2013 and chief operating officer in September 2011; together with ResMed’s chief executive officer, Michael (“Mick”) Farrell, he holds full operational responsibility for ResMed and its subsidiaries. There are no family relationships between Mr.

    Read the 8-K filing
12. Oct 7, 2021

    of our Current Report on Form 8-K of ResMed Inc. filed with the Securities and Exchange Commission on August 27, 2021 (the “Original Filing”), to add information regarding separation arrangements that were not determined or available at the time of the Original Filing.

    Read the 8-K filing
13. Aug 27, 2021

    On August 24, 2021, we determined that, effective August 25, Rajwant (“Raj”) Sodhi would cease serving as our president – Software-as-a-Service business and will cease full-time employment with us on September 1, 2021. The termination is without cause, and we are in discussions with Mr. Sodhi regarding a separation package. Effective August 25, 2021, we promoted Bobby Ghoshal, age 53, to serve as our president – Software-as-a-Service business. Mr. Ghoshal has over 25 years of experience across medical and technology industries, with strong experience building and leading high-performing teams to accelerate the adoption of digital platforms across enterprises. He has served as ResMed’s Chief Technology Officer since April 2018. From June 2016 until April 2018, Mr.

    Read the 8-K filing
14. May 16, 2019

    Departure of Directors or Principal Officers; Election of Directors; Principal Officer Appointment. Appointment of Jan De Witte to Board of Directors On May 16, 2019, ResMed Inc. appointed Jan De Witte to serve on its board of directors, with a term expiring at ResMed’s 2019 annual meeting of stockholders, or until Mr. De Witte’s earlier death, disability, resignation or removal. Mr. De Witte is the chief executive officer and member of the board of directors of Barco NV. Mr. De Witte will serve on ResMed’s audit committee. Mr. De Witte was not selected to serve on ResMed’s board of directors under any arrangement or understanding between Mr. De Witte and any other person. ResMed is not aware of any transactions with Mr. De Witte that would require disclosure under Item 404(a) of Regulation S-K.

    Read the 8-K filing
15. Nov 16, 2018

    ResMed Inc. 2018 Employee Stock Purchase Plan On November 14, 2018, US Pacific time, at the annual meeting of stockholders of ResMed, Inc., our stockholders approved an amendment to the ResMed Inc. 2009 Employee Stock Purchase Plan, which increased the number of shares of common stock we may issue or transfer by awards under the plan by 2 million shares, from 4.2 million shares to 6.2 million shares. The amendment also renamed the plan as “the ResMed Inc. 2018 Employee Stock Purchase Plan,” and extended the term of plan by ten years, so that the plan expires on November 15, 2028. The amendment became effective August 17, 2018, the date it was adopted by our board of directors. The description above is qualified in its entirety by reference to the actual terms of the ResMed Inc.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.